Xeris Biopharma (XERS) Expected to Announce Earnings on Wednesday

Xeris Biopharma (NASDAQ:XERS) will likely be releasing its earnings data before the market opens on Wednesday, March 5th. Analysts expect Xeris Biopharma to post earnings of ($0.08) per share and revenue of $58.54 million for the quarter.

Xeris Biopharma Trading Down 2.7 %

Shares of XERS stock opened at $3.66 on Wednesday. The stock has a 50 day moving average of $3.50 and a 200 day moving average of $3.19. The stock has a market cap of $545.64 million, a P/E ratio of -8.13 and a beta of 2.61. Xeris Biopharma has a twelve month low of $1.69 and a twelve month high of $4.10.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a research report on Monday, November 11th. Finally, HC Wainwright lifted their price target on Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.